Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is 1.71% higher on its value in year-to-date trading and has touched a low of $99.06 and a high of $134.17 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The JAZZ stock was last observed hovering at around $119.24 in the last trading session, with the day’s gains setting it 5.86%.
Currently trading at $125.10, the stock is 6.52% and 10.42% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.98 million and changing 4.91% at the moment leaves the stock 10.83% off its SMA200. JAZZ registered 5.77% gain for a year compared to 6-month gain of 20.36%. The firm has a 50-day simple moving average (SMA 50) of $112.9186 and a 200-day simple moving average (SMA200) of $112.8668.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 12.57% loss in the last 1 month and extending the period to 3 months gives it a 9.86%, and is 0.67% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.37% over the week and 2.81% over the month.
Jazz Pharmaceuticals plc (JAZZ) has around 2800 employees, a market worth around $7.56B and $3.99B in sales. Current P/E ratio is 18.02 and Fwd P/E is 5.78. Profit margin for the company is 11.60%. Distance from 52-week low is 26.29% and -6.76% from its 52-week high. The company has generated returns on investments over the last 12 months (4.49%).
The EPS is expected to grow by 10.84% this year
686.0 institutions hold shares in Jazz Pharmaceuticals plc (JAZZ), with institutional investors hold 101.78% of the company’s shares. The shares outstanding are 62.26M, and float is at 58.21M with Short Float at 6.17%. Institutions hold 98.79% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 6.32 million shares valued at $674.82 million. The investor’s holdings represent 10.1103 of the JAZZ Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 6.15 million shares valued at $655.94 million to account for 9.8274 of the shares outstanding. The other top investors are LSV ASSET MANAGEMENT which holds 2.48 million shares representing 3.9666 and valued at over $264.75 million, while CAPITAL WORLD INVESTORS holds 3.2294 of the shares totaling 2.02 million with a market value of $215.55 million.
Jazz Pharmaceuticals plc (JAZZ) Insider Activity
The most recent transaction is an insider sale by Patil Neena M, the company’s EVP & Chief Legal Officer. SEC filings show that Patil Neena M sold 3,700 shares of the company’s common stock on Nov 08 ’24 at a price of $123.41 per share for a total of $0.46 million. Following the sale, the insider now owns 33048.0 shares.
Still, SEC filings show that on Nov 01 ’24, COZADD BRUCE C (Chairman & CEO) disposed off 1,000 shares at an average price of $110.84 for $0.11 million. The insider now directly holds 428,976 shares of Jazz Pharmaceuticals plc (JAZZ).
